Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Advances in Hepatitis: Prevention, Treatment, and Global Health Impact
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advances in Hepatitis: Prevention, Treatment, and Global Health Impact

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 28 January 2026 | Viewed by 663

Special Issue Editors

Dr. Michał Brzdęk

E-Mail
Guest Editor
Department of Infectious Diseases, Jan Kochanowski University, Żeromskiego 5, 25-369 Kielce, Poland.
Interests: HCV; hepatitis c; HBV; hepatitis B; covid-19; sars-cov-2; microbiome; MASLD
Prof. Dr. Dorota Zarębska-Michaluk

E-Mail Website
Guest Editor
Department of Infectious Diseases, Jan Kochanowski University Kielce, Kielce, Poland
Interests: hepatitis; hepatitis B; hepatitis C; liver disease
Special Issues, Collections and Topics in MDPI journals
Dr. Krystyna Dobrowolska

E-Mail Website
Guest Editor
Collegium Medicum, Jan Kochanowski University, 25-317 Kielce, Poland
Interests: hepatitis; hepatitis B; hepatitis C; liver disease

Special Issue Information

Dear Colleagues,

Hepatitis continues to pose a substantial global health challenge, despite remarkable advancements in its prevention, diagnosis, and treatment. The advent of direct-acting antivirals (DAAs) has revolutionized hepatitis C therapy, yielding cure rates above 95%, while effective vaccination programs have curbed the spread of hepatitis B. However, inequities in access to care, particularly in low- and middle-income countries, hinder progress toward global elimination goals. This Special Issue aims to highlight innovative strategies in prevention, novel therapeutic developments, public health initiatives, and policy approaches addressing viral hepatitis. We welcome original research and reviews that explore molecular mechanisms, clinical trials, epidemiological trends, and health equity efforts. Our shared objective is to support global efforts aligned with the WHO’s 2030 targets and ultimately reduce the burden of liver disease worldwide.

Dr. Michał Brzdęk
Prof. Dr. Dorota Zarębska-Michaluk
Dr. Krystyna Dobrowolska
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatitis B
  • hepatitis C
  • liver disease
  • direct-acting antivirals (DAAs)
  • global health
  • public health policy
  • viral hepa-titis elimination
  • health disparities
  • cirrhosis
  • vaccination programs

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 452 KB  
Article
Prevalence and Trends in Active Smoking Among Adults Living with HCV in the U.S. over the Last Decade: A Population-Level Analysis
by Mohammad Alabbas, Jingyi Shi, Yuqi Guo, Hongke Wu, Ibukunoluwa Oshobu, Maria Castano, Walaa Mahmoud, Shreya Sengupta and Omar T. Sims
J. Clin. Med. 2025, 14(18), 6671; https://doi.org/10.3390/jcm14186671 - 22 Sep 2025
Viewed by 369
Abstract
Background: Smoking in patients with hepatitis C (HCV) amplifies the risk of cirrhosis and hepatocellular carcinoma. We aimed to estimate the prevalence of active smoking over the last decade at the population level among adults living with HCV in the U.S., estimate [...] Read more.
Background: Smoking in patients with hepatitis C (HCV) amplifies the risk of cirrhosis and hepatocellular carcinoma. We aimed to estimate the prevalence of active smoking over the last decade at the population level among adults living with HCV in the U.S., estimate temporal trends in active smoking, and identify factors associated with active smoking. Methods: We analyzed repeated cross-sectional NHANES data (2007–2018) of adults ≥20 years old with serologic evidence of HCV and complete smoking data (unweighted [n = 621] and weighted [n = 3,620,603] sample size). Temporal trends were evaluated using linear regression and joinpoint regression. Survey-weighted multivariable logistic regression was used to identify factors associated with active smoking. Results: The cumulative prevalence of active smoking was 56.4% (95% CI, 49.2–63.4). Linear trend testing was not significant (p = 0.93). Joinpoint regression suggested a slope change near 2013–2014, but neither segment-specific annual percent changes nor the slope change reached significance. Factors associated with higher odds of active smoking included female sex (aOR = 2.23; 95% CI, 1.17–4.24), low poverty income ratio (aOR = 3.33; 1.41–7.84), lifetime substance use (aOR = 10.63; 3.08–36.70), and depression (aOR = 2.65; 1.29–5.45). Lower odds were observed with >high-school education (aOR = 0.50; 0.26–0.94), obesity (aOR = 0.32; 0.18–0.58), and ≥2 yearly healthcare visits (aOR = 0.27; 0.10–0.68). Conclusions: Smoking appears to be endemic within the HCV population, and rates have remained alarmingly high and stagnant (i.e., unchanged or have not decreased) over the last decade, which consequently can lead to heightened incident cases of HCV-related cirrhosis and hepatocellular carcinoma in the near future. Full article
(This article belongs to the Special Issue Advances in Hepatitis: Prevention, Treatment, and Global Health Impact)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop